Tuesday, 07 Apr 2020

You are here

Taltz FDA Approved for Ankylosing Spondylitis (Radiographic Axial SpA)

The FDA has approved the IL-17A inhibitor Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis (AS: also known as radiographic axial spondyloarthritis).  

The recommended dose is 160 mg SC (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.  The updated package insert can be found here.

According to Lilly, there are 1.6 million people in the US with ankylosing spondylitis, but only 15% of patients with the condition are taking biologic therapies.

Approval is based on the COAST trials in AS. The COAST-V trial studied IXE in biologic naive AS/SpA patients and the COAST-W trial involved patients previously to TNF inhibitors.

In COAST-V, IXE achieved ASAS40 of 48%, compared with 18% of placebo (P < .0001) treated patients. ASAS40 response rates in COAST-W were 25% with ixekizumab vs 13% with placebo (P <0.05).

There are no serious "boxed" warnings.  Other warnings and precautions include:

  • Serious infections
  • Tuberculosis (TB): Evaluate for TB prior to initiating treatment
  • Hypersensitivity: If a serious allergic reaction occurs, discontinue TALTZ
  • Inflammatory Bowel Disease: Crohn’s disease and ulcerative colitis, including exacerbations, occurred in clinical trials

Ixekizumab (IXE) was previously \approved in March 2016 for plaque psoriasis and in December 2017 for psoriatic arthritis.

This will be the second IL-17 targeted biologic (along with Cosentyx) approved by the FDA for ankylosing spondylitis.

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

No Cancer Increase in Psoriatic Arthritis or with Biologics in Psoriasis

JAMA Dermatology reports that psoriasis is associated with a slightly increased risk of cancer, particularly keratinocyte cancer and lymphomas.

A systematic review and meta-analysis of 112 studies including more than 2 million patients, also shows no increase in when psoriasis is treated with biologic agents, nor was psoriatic arthritis associated with an increased risk of cancer.   

Bimekizumab Effective in Active Psoriatic Arthritis

Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a noveal approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement.

Upadacitinib Effective in Phase 3 Psoriatic Arthritis Study

Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.

Which Biologics are Best in Psoriasis

A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.